Print PDF

Sheppard Mullin Represents Aridis Pharmaceuticals in $26 million IPO


The firm represented Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections, in its $26 million IPO. Announced on August 13, the IPO was led by Cantor Fitzgerald & Co. The Sheppard Mullin team included partners Jeff Fessler, Lorna Tanner, Alex Nie and Peter Reichertz, and associates Justin Anslow, Nazia Khan, and Joy Nemirow.

Click here to read more.

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.